This inventor holds 2 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Herantis Pharma Plc.. Active years: 2014-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2017
Title: The Impact of Mikko Airavaara in Neuronal Disorder Treatments
Introduction
Mikko Airavaara, an innovative inventor based in Annapolis, MD, has made significant contributions in the field of neuroscience. With two patents to his name, Airavaara is recognized for his work on neurotrophic factors, particularly in the treatment of various neuronal disorders. His inventions hold promise for addressing debilitating conditions that affect millions globally.
Latest Patents
Airavaara's most recent patents focus on the neurotrophic factor MANF and its potential uses. The core of his invention relates to a pharmaceutical compound that includes the MANF nucleic acid molecule, MANF protein, or a functional fragment of these components. The applicability of this invention covers treatments for peripheral neuropathies, including devastating conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction, and ischemic brain injury. These contributions are not only pioneering but hold the potential to change therapeutic approaches in the field of neurology.
Career Highlights
Currently, Mikko Airavaara is affiliated with Herantis Pharma Plc, where he applies his expertise to further advancements in pharmaceutical solutions for neurological diseases. His dedication to innovation in the field has led to the development of potentially life-changing therapies.
Collaborations
Airavaara collaborates with noted professionals in his field, including Mart Saarma and Merja Voutilainen. These partnerships facilitate a dynamic exchange of ideas and enhance the scope of research and development efforts in neuronal disorder treatments.
Conclusion
Mikko Airavaara's contributions to the field of neuroscience, particularly through his work on the neurotrophic factor MANF, underscore the importance of innovation in developing strategies to combat neuronal disorders. As he continues his work with Herantis Pharma Plc and collaborates with esteemed colleagues, his research is set to create a positive impact on future therapeutic avenues for neurological health.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile